Skip to main content

Table 1 Genomic characterization, growth kinetics and sensitivity towards PLX4032 for a panel of human melanoma cell lines.

From: Differential sensitivity of melanoma cell lines with BRAFV600Emutation to the specific Raf inhibitor PLX4032

Cell Line NRAS/BRAF Number of BRAF Gene Copies Other Oncogenic Events Cell line doubling time (hours) PLX4032 IC50 (μM)
M257 Wild type 3 CDKN2A R80 31.4 Not reached
M202 NRAS Q61L 2 EGFR amplification
CDKN2A homozygous deletion
26.1 Not reached
M207 NRAS Q61L 2 MITF amplification
PTEN heterozygous deletion
25.2 Not reached
M233 BRAFV600E Heterozygous 3 AKT1 amplification
CCND1 amplification
EGFR amplification
CDKN2A homozygous deletion
PTEN homozygous deletion
29.6 Not reached
M255 BRAFV600E Heterozygous 2 AKT2 amplification
CCND1 amplification
EGFR amplification
CDKN2A homozygous deletion
48.6 Not reached
M308 BRAFV600E Heterozygous 3 MITF amplification
AKT2 amplification
EGFR amplification
CDKN2A heterozygous deletion
35.0 Not reached
M263 BRAFV600E Heterozygous 2 CDKN2A heterozygous deletion 23.3 10
M321 BRAFV600E Homozygous 2   34.1 7.5
SKMEL28 BRAFV600E Homozygous 2 EGFR P753S
MITF amplification
CCND1 amplification
CDKN2A heterozygous deletion
PTEN heterozygous deletion
26.9 4.6
M229 BRAFV600E Homozygous 4 MITF amplification
AKT1 amplification
PTEN heterozygous deletion
27.9 0.2
M238 BRAFV600E Heterozygous 2 CDKN2A homozygous deletion
PTEN heterozygous deletion
28.1 0.7
M249 BRAFV600E Heterozygous 3 MITF amplification
AKT2 amplification
PTEN homozygous deletion
21.2 0.8
M262 BRAFV600E Homozygous 2 AKT1 E17K
AKT1 amplification
EGFR amplification
CDKN2A homozygous deletion
47.4 0.1
\